Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brexit Stakes Rise As New UK Prime Minister Takes Over

Executive Summary

The UK has a new prime minister in Boris Johnson, who is likely to surround himself with strongly pro-Brexit ministers. The life sciences industry will need to continue lobbying for its interests to be protected in the event of a no-deal exit.

You may also be interested in...



BIA Presses New UK Government On No-Deal Brexit Preparations

The life sciences industry has given a cautious welcome to the prime minister’s promises that the sector will be a priority once the UK leaves the EU, but has urged the new UK government to take steps to protect medicine supply chains in the event of a no-deal Brexit. 

UK Brushes Up No-Deal Brexit Legislation

Some changes have been made to UK legislation that will aim to ensure the effective operation of the regulatory system once the country leaves the EU. Areas affected include the QPPV, pediatric and orphan medicines, and the reference product for generic approvals.

UK Pharma Decries Govt's Latest No-Deal Brexit Planning

The provision of “express” freight capacity for medicines that need to be delivered urgently is among the latest proposals from the UK government to help cope with supply disruptions in the event of a no-deal Brexit. But the biopharmaceutical industry says some of the proposals are too short notice and will place additional burdens on companies.

Related Content

Topics

UsernamePublicRestriction

Register

PS140561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel